BLAINTRAVENOUSPOWDER, FOR SOLUTION
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Balfaxar (prothrombin complex concentrate (human)) by Octapharma is 12. First approved in 2023.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Balfaxar is a human prothrombin complex concentrate (IV powder) that rapidly restores plasma levels of vitamin K-dependent coagulation factors (II, VII, IX, X) and antithrombotic proteins C and S. It corrects coagulation defects in patients deficient in one or more of these factors, with median INR reduction from 3.0 to 1.30 within 30 minutes of infusion. The product is indicated for urgent reversal of anticoagulation and management of hemorrhage in specialized clinical settings.
Growth
Early-stage growth product with recent FDA approval positions the brand team for commercial expansion, though current job pipeline is limited.
Mechanism of Action
12.1 Mechanism of Action The administration of BALFAXAR provides a rapid increase in plasma levels of the vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) and antithrombotic proteins C and S. Together they are referred to/known as the prothrombin complex. [ ; ] BALFAXAR can temporarily…
Worked on Balfaxar at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.